The XENERA™-1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Post-menopausal Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

Official Title

XENERA™-1: A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Post-menopausal Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease

Summary:

The main objective of the trial is to assess the anti-tumour activity of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in post menopausal patients with HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease.

Trial Description

Primary Outcome:

  • Progression free survival (PFS) as assessed by central review
Secondary Outcome:
  • Overall survival (OS) defined as the time from randomisation until death from any cause
  • Disease control (DC)
  • Duration of DC is defined as the time from randomisation until the earliest of disease progression or death, among patients with DC
  • Objective response (OR) Defined as a best overall response of complete response (CR) or partial response (PR)
  • Time to pain progression or intensification of pain palliation

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society